The French Government Defence procurement agency invests €900,000 towards Pherecydes Pharma managed €1.2-million project, involving several university and military laboratories.
Pherecydes Pharma is attending the Forum coorganised by PHAG ESPOIRS and LE LIEN associations, as well as their partners, Narbonne Hospital and City, on January 25, 2012 in Narbonne - France, at 9h15, in Le Théatre.
Biotech Finance press details the purpose of this investiment targeting the set up of a phage bioproduction unit and testing of 2 therapeutic products in human clinical trials.
Meeting the Belgian biotech companies at the 2011 Forum Bio-Entrepreneurs held in the Bourse de Commerce de Paris, December 6, 2011.
Presentation
Pherecydes Pharma is a SA (Société anonyme à directoire et conseil de surveillance) incorporated in December 2006. The company strategy is investing in innovation, to build added value through patents and technology platforms. Today our advances hold promises in several business areas from drug discovery to nanotechnologies. At this stage of development Pherecydes Pharma is open to develop industrial applications in the most promising ones, to focus on one or two key industrial sectors.
Please, click on this link to download our corporate profile.
You can visualize, as well, a presentation of the company by clicking here.
A state of the art facility within Biocitech Technology Park
- An ideal situation within a secured park dedicated to biotechnology and other high technology fields
- Pherecydes Pharma holds the right to operate with harmful bacteria and genetically modified organisms
- Pherecydes Pharma manages 115 m² of laboratories at Biocitech, including an isolated new L2 area, dedicated to infectious bacteria
click on image to enlarge